Login to Your Account

Par Pharmaceutical Gains Rights To Phase III Drug From Immtech

By Jim Shrine

Wednesday, June 13, 2007
Par Pharmaceutical Cos. Inc. gained exclusive rights in the U.S. to a Phase III drug from Immtech Pharmaceuticals Inc. for treating pneumocystis pneumonia in AIDS patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription